Closing the gap between industry and academia to place patients directly at the center of research efforts. , Jan. 6, 2022 /PRNewswire/ – LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic approach in Long QT syndrome” was selected for […]